Effects of Selenium and/or N-Acetyl-Cysteine Supplementation on Nonthyroidal Illness Syndrome in Hemodialysis Patients: A Factorial Randomized Controlled Trial.

التفاصيل البيبلوغرافية
العنوان:	Effects of Selenium and/or N-Acetyl-Cysteine Supplementation on Nonthyroidal Illness Syndrome in Hemodialysis Patients: A Factorial Randomized Controlled Trial.
المؤلفون:	Shahreki E; Department of Nephrology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran., Kaykhaei MA; Genetics of Noncomunicable Disease Research Center, Zahedan University of Medical Sciences, Zahedan, Iran., Mosallanezhad Z; Nutrition Research Center, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran., Adineh Z; Department of Internal Medicine, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran., Mokhtari AM; Department of Epidemiology and Biostatistics, School of Health, Social Development and Health Promotion Research Center, Gonabad University of Medical Sciences, Gonabad, Iran., Mohammadi M; Department of Biostatistics and Epidemiology, School of Health Promotion Research Center, Zahedan University of Medical Sciences, Zahedan, Iran., Hosseini R; Nutrition Research Center, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran., Bazi A; Department of Clinical Pharmacy, Faculty of Pharmacy, Zabol University of Medical Sciences, Zabol, Iran.
المصدر:	Pharmacology [Pharmacology] 2022; Vol. 107 (9-10), pp. 480-485. Date of Electronic Publication: 2022 Jun 10.
نوع المنشور:	Journal Article; Randomized Controlled Trial
اللغة:	English
بيانات الدورية:	Publisher: Karger Country of Publication: Switzerland NLM ID: 0152016 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1423-0313 (Electronic) Linking ISSN: 00317012 NLM ISO Abbreviation: Pharmacology Subsets: MEDLINE
أسماء مطبوعة:	Original Publication: Basel (Switzerland) : Karger,
مواضيع طبية MeSH:	Selenium*/pharmacology, Acetylcysteine/therapeutic use ; Dietary Supplements ; Humans ; Renal Dialysis/adverse effects ; Thyrotropin
مستخلص:	Introduction: Nonthyroidal illness syndrome (NTIS) is common in hemodialysis patients (HPs). However, limited clinical trials have been conducted in this field. Therefore, the aim of this study was to investigate the effect of Se and/or N-acetyl-cysteine (NAC) on NTIS parameters in HPs. Methods: In this factorial randomized controlled trial, 68 HPs were divided into four groups: group A received placebo of Se and NAC, group B received 600 μg per day of NAC and placebo of Se, group C received 200 μg of Se per day and placebo of NAC and group D received 200 μg of selenium and 600 μg of NAC per day for 12 weeks. Blood samples were taken at baseline and after 12 weeks to assess free tri-iodothyronine (FT3), free thyroxine (FT4), thyroid stimulating hormone (TSH), and reverse T3 (rT3) concentrations. Results: Our finding demonstrated that rT3 levels were decreased in B, C, and D groups and increased nearly to baseline levels in the A group after 12 weeks, with a marked difference between the groups (p < 0.001) based on ANOVA. Although there were no significant differences in FT3 (p = 0.39), FT4 (p = 0.76), and TSH (p = 0.71) between the groups at the end of the trial. Conclusion: This trial showed that Se and/or NAC exert beneficial effects on rT3 levels in HPs. However, long-term clinical trials with a larger sample size using more appropriate biomarkers are recommended to evaluate the efficacy and safety of Se and/or NAC in HPs. (© 2022 S. Karger AG, Basel.)
فهرسة مساهمة:	Keywords: Hemodialysis patients; N-acetyl-cysteine; Nonthyroidal illness syndrome; Selenium
المشرفين على المادة:	9002-71-5 (Thyrotropin) H6241UJ22B (Selenium) WYQ7N0BPYC (Acetylcysteine)
تواريخ الأحداث:	Date Created: 20220612 Date Completed: 20220907 Latest Revision: 20220907
رمز التحديث:	20221213
DOI:	10.1159/000525094
PMID:	35691282
قاعدة البيانات:	MEDLINE

Full Text Finder

الوصف
تدمد:	1423-0313
DOI:	10.1159/000525094